CD4 News and Research

RSS

Phase I clinical trials reveal MVA-B preventive vaccine's immune efficiency against HIV

Phase I clinical trials developed by Spanish Superior Scientific Research Council (CSIC) together with Gregorio Mara--n Hospital in Madrid and Cl-nic Hospital in Barcelona, reveals MVA-B preventive vaccine's immune efficiency against Human's immunodeficiency virus (HIV).

28 Sep 2011

Study sheds light on when to start antiretroviral therapy

Findings from a study published in the current issue of the journal Archives of Internal Medicine, when "taken together with other studies published over the last few years," show that beginning people living with HIV on highly active antiretroviral therapy (HAART) when their CD4 cell count is between 350 and 500 "appears to be beneficial over the long term.

28 Sep 2011

Early ART cost effectiveness in resource-poor settings

A study published in PLoS Medicine shows "that the new WHO guidelines for early [antiretroviral treatment (ART)] initiation can be cost-effective in resource-poor settings, information that should help policymakers in developing countries allocate their often limited resources," according to a PLoS press release.

22 Sep 2011

Early ART can be cost-effective and decrease mortality in HIV patients

Researchers at Weill Cornell Medical College and GHESKIO have shown that early treatment of HIV not only saves lives but is also cost-effective. Results are published in today's edition of PLoS Medicine.

22 Sep 2011

Inovio achieves best-in-class immune responses in PENNVAX-B HIV vaccine Phase I study

Inovio Pharmaceuticals, Inc., a leader in the development of synthetic immunogens against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in a Phase I clinical study of PENNVAX-B, its product for the prevention of the HIV sub-type prevalent in the US and Europe.

14 Sep 2011

Rwanda to treat HIV-positive people in discordant relationships as soon as they test positive

After a landmark study published in May "showed major reductions in HIV transmission among discordant couples due to early treatment," Rwanda has decided to begin treating people in discordant relationships with antiretroviral therapy as soon as they test HIV-positive "as part of a plan to boost national HIV prevention and treatment efforts," PlusNews reports.

14 Sep 2011

IKEPLUS immunization completely eliminates TB bacteria from infected tissues

A potential vaccine against tuberculosis has been found to completely eliminate tuberculosis bacteria from infected tissues in some mice. The vaccine was created with a strain of bacteria that, due to the absence of a few genes, are unable to avoid its host's first-line immune response.

5 Sep 2011

Researchers reveal specific process by which HIV virus infects healthy T cells

A George Mason University researcher team has revealed the specific process by which the HIV virus infects healthy T cells-a process previously unknown. The principal investigator, HIV researcher Yuntao Wu, says he hopes this breakthrough will start a new line on inquiry into how researchers can use this knowledge to create drugs that could limit or halt HIV infection.

25 Aug 2011

South Africa expands AIDS program to allow earlier ARV treatment

The South African National AIDS Council (SANAC) on Saturday endorsed a new National Health Council policy to expand the country's AIDS program "to allow people living with HIV to start antiretroviral [ARV] treatment earlier" by raising the CD4 count necessary to access treatment from 200 to 350, Agence France-Presse reports.

16 Aug 2011

New technique can help develop HIV vaccines

Researchers have traced in detail how certain powerful HIV neutralizing antibodies evolve, a finding that generates vital clues to guide the design of a preventive HIV vaccine, according to a study appearing in Science Express this week.

12 Aug 2011

Cancer-causing fusion protein works by silencing tumor suppressor gene IL-2Rγ

Mariusz A. Wasik, MD, professor of Pathology and Laboratory Medicine, and Qian Zhang, MD, PhD, research assistant professor, both from the Perelman School of Medicine at the University of Pennsylvania, and their colleagues, found that a cancer-causing fusion protein works by silencing the tumor suppressor gene IL-2R common gamma-chain.

10 Aug 2011

Control and elimination of neglected tropical diseases can help treat HIV/AIDS

There is a growing body of evidence revealing the connection between neglected tropical diseases (NTDs) and HIV/AIDS, prompting experts to call for greater integration of national NTD treatment programs with HIV/AIDS initiatives.

28 Jul 2011

Early initiation of HIV therapy would save money, lives of South Africans

If the South African government followed a recent recommendation by the World Health Organization to start antiretroviral therapy (ART) for HIV-infected residents earlier in the progress of the disease, the policy shift would start saving the country money after 16 years and would extend thousands of lives for dozens of years, according to a new study.

27 Jul 2011

Nanoviricides lead anti-HIV candidate as good as HAART cocktail therapy

NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.

25 Jul 2011

New trends in HIV cure research presented at IAS 2011

Researchers speaking on the final day of the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) have focused on the growing interest in the scientific path to an HIV Cure.

20 Jul 2011

IAS conference opens with push for treatment as prevention

The 6th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention taking place in Rome this week "started optimistically as the hype surrounding the use of antiretroviral treatment to prevent HIV infection gained momentum. But the focus of much discussion … will undoubtedly be on how to transform the recent promising research findings into workable policy," PlusNews reports.

20 Jul 2011

ISENTRESS demonstrates comparable efficacy to efavirenz in treatment-naïve adult HIV-1 patients

Merck, known as MSD outside the United States and Canada, today announced final results from a Phase II clinical study, extending out to 240 weeks, of its integrase inhibitor ISENTRESS® (raltegravir) Tablets in combination therapy in previously untreated (treatment-naïve) adult HIV-1-infected patients.

18 Jul 2011